載入中
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
收盤時
US$0.832
+US$0.0217 · +2.68%
盤後
US$0.839
+US$0.007 · +0.84%
10月12日 下午4:41 ET
盤中時間採用ET。市場資料可能有所延遲。
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
日內區間
目前US$0.832
52週區間
目前US$0.832
盤中時間採用ET。市場資料可能有所延遲。
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
日內區間
目前US$0.832
52週區間
目前US$0.832
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 16萬 USD | 16萬 USD | 16萬 USD | 9.8萬 USD |
| 毛利 | — | −16萬 USD | −16萬 USD | −16萬 USD | −9.8萬 USD |
| 研究與開發 | 213.5萬 USD | 41.4萬 USD | 8.2萬 USD | 8.7萬 USD | 18.3萬 USD |
| 銷售、一般及管理費用 | 343.7萬 USD | 176.9萬 USD | 147.2萬 USD | 32.4萬 USD | 166.2萬 USD |
| 營業費用 | 557.2萬 USD | 218.3萬 USD | 155.4萬 USD | 41.1萬 USD | 184.5萬 USD |
| 利息收入 | 12.5萬 USD | — | — | — | — |
| 利息支出 | — | 85.9萬 USD | 9.8萬 USD | 47.9萬 USD | 20.2萬 USD |
| 折舊和攤銷 | 16萬 USD | 16萬 USD | 16萬 USD | 16萬 USD | 9.8萬 USD |
| 營業利益 | −557.2萬 USD | −234.3萬 USD | −171.4萬 USD | −57.1萬 USD | −194.3萬 USD |
| 淨利 | −544.7萬 USD | −260.3萬 USD | −181.2萬 USD | −105萬 USD | −214.5萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
